A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine

A Randomized, Double-blind, Positive-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C (A Bivalent SARS-CoV-2 Trimeric Spike Protein Vaccine) in Population Aged ≥18 Years Previously Fully Vaccinated With Either Inactivated or mRNA COVID-19 Vaccine or Previously Diagnosed With COVID-19

The objective of this study is to evaluate the immunogenicity and safety of SCTV01C in participants aged ≥18 years and previously fully immunized with either inactivated or mRNA COVID-19 vaccine or previously diagnosed with COVID-19.

Study Overview

• Status: Not yet recruiting
• Conditions: COVID-19; SARS-CoV-2 Infection
• Intervention / Treatment: Biological: SCTV01C; Biological: Sinopharm inactivated COVID-19 vaccine; Biological: Comirnaty

Detailed Description

The study is a randomized, double-blind, positive-controlled Phase II booster study. It will evaluate the immunogenicity and safety of SCTV01C compared with either Sinopharm inactivated COVID-19 vaccine or Comirnaty in participants aged ≥18 years and previously fully immunized with either inactivated or mRNA COVID-19 vaccine or previously diagnosed with COVID-19.

• Study Type: Interventional
• Enrollment (Anticipated): 600
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male or female aged ≥18 years old when signing ICF;
2. For Cohort 1: Participants who were fully vaccinated with 2 doses of inactivated COVID-19 vaccine (Sinopharm inactivated COVID-19 vaccine) or previously diagnosed with COVID-19. The interval between the last dose and this study vaccination is ≥3 months and ≤12 months. The interval between the last day diagnosed with COVID-19 and this study vaccination is ≥3 months and ≤12 months; For Cohort 2: Participants who were fully vaccinated with 2 doses of mRNA COVID-19 vaccine (Comirnaty from Pfizer or mRNA-1273 from Moderna) or previously diagnosed with COVID-19. The interval between the last dose and this study vaccination is ≥3 months and ≤12 months. The interval between the last day diagnosed with COVID-19 and this study vaccination is ≥3 months and ≤12 months;
3. The participant can sign the written ICF (by applying his / her signature or fingerprint "for illiterate subject"), and can fully understand the trial procedure, the risk of participating in the trial, and other interventions that can be selected if they do not participate in the trial;
4. The participant and/or his entrusted person has the ability to read, understand, and fill in record cards;
5. Healthy participants or participants with pre-existing medical conditions who are in stable condition. The "pre-existing medical conditions" include but not limited to hypertension, diabetes, chronic cholecystitis and cholelithiasis, chronic gastritis that meet the described criteria. A stable medical condition is defined as disease not requiring significant change in therapy or no need for hospitalization as a consequence of worsening disease state for at least 3 months prior to enrollment;
6. Fertile men and women of childbearing potential voluntarily agree to take effective contraceptive measures from signing ICF to 6 months after the study vaccination; the pregnancy test results of women of childbearing potential are negative on screening.

Exclusion Criteria:

1. Presence of fever within 3 days before the study vaccination;
2. A history of infection or disease related to severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), or other disease with corresponding use of immunosuppressants;
3. A history of allergic reactions to any vaccine or drug, such as allergy, urticaria, severe skin eczema, dyspnea, laryngeal edema, and angioneurotic edema;
4. A medical or family history of seizure, epilepsy, encephalopathy and psychosis;
5. Immunocompromised patients suffering from immunodeficiency diseases, important organ diseases, immune diseases (including Guillain-Barre Syndrome [GBS], systemic lupus erythematosus, rheumatoid arthritis, asplenia or splenectomy caused by any circumstances, and other immune diseases that may have an impact on immune response in the investigator's opinion), etc.;
6. Long-term use of immunosuppressant therapy or immunomodulatory drugs for ≥14 days within the first six months prior to enrollment. Whereas short-term (≤14 days) use of oral, inhaled and topical steroids are allowed;
7. Patients on antituberculosis therapy;
8. Presence of severe or uncontrollable cardiovascular diseases, or severe or uncontrollable disorders related to endocrine system, blood and lymphatic system, liver and kidney, respiratory system, metabolic and skeletal systems, or malignancies (skin basal cell carcinoma and carcinoma in-situ of cervix are exceptions and will not be excluded), such as severe heart failure, severe pulmonary heart disease, unstable angina, liver failure, or uremia;
9. Contraindications for intramuscular injection or intravenous blood sampling, including thrombocytopenia and other blood coagulation disorders;
10. Participants who received any immunoglobulin or blood products in the previous 3 months before enrollment, or plan to receive similar products during the study;
11. Participants who received other investigational drugs within 1 month before the study vaccination;
12. Participants who is at the acute state of disease, such as acute onset of chronic heart failure, acute sore throat, hypertensive encephalopathy, acute pneumonia, acute renal insufficiency, acute cholecystitis;
13. Participants received other drugs or vaccines used to prevent COVID-19, but participants previously received Sinopharm inactivated COVID-19 vaccine, Comirnaty or mRNA-1273 will not be excluded;
14. Participants vaccinated with influenza vaccine within 14 days or with other vaccines within 28 days before the study vaccination;
15. Those who donated blood or had blood loss (≥450 mL) within 3 months before the vaccination or plan to donate blood during the study period;
16. Those who are pregnant or breast-feeding or plan to be pregnant during the study period;
17. Those who plan to donate ovum or sperms during the study period;
18. Those who cannot follow the trial procedures, or cannot cooperate to complete the study due to planned relocation or long-term outing;
19. Those unsuitable for participating in the clinical trial as determined by the investigator because of other abnormalities that are likely to confuse the study results, or non-conformance with the maximal benefits of the participants;
20. Those who are tested positive for HIV in terms of serology.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort 1: SCTV01C	Biological: SCTV01C; intramuscular injection
Active Comparator: Cohort 1: Sinopharm inactivated COVID-19 vaccine	Biological: Sinopharm inactivated COVID-19 vaccine; intramuscular injection
Experimental: Cohort 2: SCTV01C	Biological: SCTV01C; intramuscular injection
Active Comparator: Cohort 2: Comirnaty	Biological: Comirnaty; intramuscular injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Cohort 1: GMT of neutralizing antibodies to Delta (B.1.617.2) variant on D28.	Day 28 after the study vaccination
Cohort 1: GMT of neutralizing antibodies to Omicron (B.1.1.529) variant on D28	Day 28 after the study vaccination
Cohort 1: Incidence and severity of solicited AEs from D0 to D7 after study vaccination.	Day 0 to Day 7 after the study vaccination
Cohort 1: Incidence and severity of unsolicited AEs from D0 to D28 after study vaccination.	Day 0 to Day 28 after the study vaccination
Cohort 2: GMT of neutralizing antibodies to Delta (B.1.617.2) variant on D28.	Day 28 after the study vaccination
Cohort 2: Incidence and severity of solicited AEs from D0 to D7 after study vaccination.	Day 0 to Day 7 after the study vaccination
Cohort 2: Incidence and severity of unsolicited AEs from D0 to D28 after study vaccination.	Day 0 to Day 28 after the study vaccination

Secondary Outcome Measures

Outcome Measure	Time Frame
Cohort 1: Number of IFN-γ positive (characterizing Th1) and IL-4 positive (characterizing Th2) T cell subsets on D28.	Day 28 after the study vaccination
Cohort 1: Seroresponse rates of neutralizing antibodies to Delta variant on D28.	Day 28 after the study vaccination
Cohort 1: Seroresponse rates of neutralizing antibodies to Omicron variant on D28.	Day 28 after the study vaccination
Cohort 1: GMT of neutralizing antibodies to Delta (B.1.617.2) variant on D28 in different subgroup.	Day 28 after the study vaccination
Cohort 1: GMT of neutralizing antibodies to Omicron (B.1.1.529) variant on D28 in different subgroup.	Day 28 after the study vaccination
Cohort 1: Incidence and severity of SAEs and AESIs within 180 days after study vaccination.	Day 28 after the study vaccination
Cohort 2: Number of IFN-γ positive (characterizing Th1) and IL-4 positive (characterizing Th2) T cell subsets on D28.	Day 28 after the study vaccination
Cohort 2: Seroresponse rates of neutralizing antibodies to Delta variant on D28.	Day 28 after the study vaccination
Cohort 2: Seroresponse rates of neutralizing antibodies to Omicron variant on D28.	Day 28 after the study vaccination
Cohort 2: GMT of neutralizing antibodies to Omicron (B.1.1.529) variant on D28.	Day 28 after the study vaccination
Cohort 2: Cohort 1: GMT of neutralizing antibodies to Delta (B.1.617.2) variant on D28 in different subgroup.	Day 28 after the study vaccination
Cohort 2: Cohort 1: GMT of neutralizing antibodies to Omicron (B.1.1.529) variant on D28 in different subgroup.	Day 28 after the study vaccination
Cohort 2: Incidence and severity of SAEs and AESIs within 180 days after study vaccination.	Day 0 to Day 180 after the study vaccination

Collaborators and Investigators

• Sponsor: Sinocelltech Ltd.

Study record dates

Study Major Dates

• Study Start (Anticipated): March 20, 2022
• Primary Completion (Anticipated): July 1, 2022
• Study Completion (Anticipated): December 1, 2022

Study Registration Dates

• First Submitted: February 11, 2022
• First Submitted That Met QC Criteria: February 11, 2022
• First Posted (Actual): February 14, 2022

Study Record Updates

• Last Update Posted (Actual): March 2, 2022
• Last Update Submitted That Met QC Criteria: February 14, 2022
• Last Verified: February 1, 2022

More Information

Terms related to this study

• Keywords: Vaccine; COVID-19; SARS-CoV-2 infection
• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: SCTV01C-01-JOR-1

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No